NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $36.18 -0.26 (-0.71%) As of 02:19 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nektar Therapeutics Stock (NASDAQ:NKTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$35.41▼$36.5050-Day Range$35.78▼$75.4452-Week Range$33.40▼$109.00Volume270,055 shsAverage Volume1.06 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$130.33Consensus RatingModerate Buy Company Overview Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work. Its research has included polymer-conjugation technologies intended to improve the properties of medicines.AI Generated. May Contain Errors. Read More Nektar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreNKTR MarketRank™: 2.564374834085 of 5 starsNektar Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 512th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 10 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialNektar Therapeutics has a consensus price target of $130.33, representing about 265.3% upside from its current price of $35.68.Amount of Analyst CoverageNektar Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nektar Therapeutics are expected to decrease in the coming year, from ($8.08) to ($11.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.33% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 10.26, which indicates bearish sentiment.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.22 News SentimentNektar Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Nektar Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 5 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,476.00 in company stock.Percentage Held by Insiders2.50% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTR Stock News HeadlinesNektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript3 hours ago | seekingalpha.comNektar Therapeutics Earnings Call Signals Clinical MomentumNovember 16 at 2:30 PM | theglobeandmail.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)Nektar Therapeutics: Buy Reiterated at $185 on Rezpeg Expansion and ZENITH ProgressNovember 16 at 6:51 AM | tipranks.comOppenheimer Remains a Buy on Nektar Therapeutics (NKTR)November 15 at 1:04 AM | theglobeandmail.comPiper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)November 15 at 1:04 AM | theglobeandmail.comNektar Therapeutics (NASDAQ:NKTR) Stock Moved Down to Sell by Wall Street ZenNovember 14 at 1:48 AM | americanbankingnews.comNektar (NKTR) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $42.28 at the beginning of the year. Since then, NKTR stock has decreased by 15.6% and is now trading at $35.6820. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. The biopharmaceutical company had revenue of $9.39 million for the quarter, compared to analysts' expectations of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative trailing twelve-month return on equity of 33.89%. Read the conference call transcript. When did Nektar Therapeutics' stock split? Nektar Therapeutics shares reverse split on Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' top institutional shareholders include Two Seas Capital LP (9.80%), State Street Corp (5.19%), Goldman Sachs Group Inc. (1.82%) and K2 Principal Fund L.P. (0.31%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Robert Chess and Jonathan Zalevsky. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (XYZ). Company Calendar Last Earnings11/12/2026Today11/17/2026UBS Global Biopharma Conference 202611/17/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NKTR's financial health is in the Red zone, according to TradeSmith. NKTR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NKTR CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees63Year Founded1990Price Target and Rating Average Price Target for Nektar Therapeutics$130.33 High Price Target$192.00 Low Price Target$50.00 Potential Upside/Downside+260.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($6.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.08 million Net Margins-339.67% Pretax Margin-280.48% Return on Equity-33.89% Return on Assets-24.86% Debt Debt-to-Equity RatioN/A Current Ratio10.42 Quick Ratio10.42 Sales & Book Value Annual Sales$55.23 million Price / Sales22.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book8.21Miscellaneous Outstanding Shares34,140,000Free Float33,289,000Market Cap$1.24 billion OptionableOptionable Beta1.44 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NKTR) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.